Related by context. All words. (Click for frequent words.) 83 Chronic Hepatitis B 81 Meets Primary Endpoint 81 Infected Patients 81 Advanced Melanoma 81 Pooled Analysis 80 Newly Diagnosed Multiple Myeloma 80 Previously Treated 80 Antitumor Activity 80 Phase 2b Clinical Trial 80 Study Evaluating 80 Relapsed Refractory 80 Peginterferon Alfa 2a 79 Treatment Experienced 79 Oral Fingolimod 79 Monotherapy 79 Previously Untreated 79 Survival Benefit 79 Severe Sepsis 79 Patients Treated 78 Improves Survival 78 Metastatic Colorectal Cancer 78 Castration Resistant Prostate Cancer 78 Treatment Naive Patients 78 Clinical Trial Results 78 Prolongs Survival 78 Anti Tumor Activity 78 Patients Treated With 78 Relapsing Multiple Sclerosis 78 Peginterferon 78 Drug Candidate 77 Complicated Skin 77 Advanced Prostate Cancer 77 Phase IIb Trial 77 Protease Inhibitor 77 Adjuvant Treatment 77 Novel Oral 77 Metastatic Prostate Cancer 77 Demonstrates Significant 77 Well Tolerated 77 Advanced Colorectal Cancer 77 Treatment Naïve 77 Renal Cell Carcinoma 77 Adjuvant Chemotherapy 77 Adjuvant Therapy 77 Improves Outcomes 77 Postmenopausal Women 76 Unresectable 76 HCV Protease Inhibitor 76 Completes Enrollment 76 Demonstrates Positive 76 Plus Ribavirin 76 Hormone Refractory Prostate Cancer 76 Randomized Phase 76 Rheumatoid Arthritis Patients 76 Pharmacokinetic Study 76 Combination Treatment 75 Receives Orphan Drug Designation 75 Controlled Trial 75 Randomized Double Blind 75 Soft Tissue Sarcoma 75 Long Term Efficacy 75 Trial Evaluating 75 Is Well Tolerated 75 Elderly Patients 75 Anti Tumor 75 Dose Escalation 75 Myeloma Patients 75 Advanced Renal Cell 75 Combination Therapy 75 Advanced Ovarian Cancer 75 Advanced Pancreatic Cancer 75 Phase 2b Trial 75 Patients Suffering 75 Hemodialysis Patients 75 Investigational Compound 75 Demonstrates Potent 75 Antiviral Activity 75 Meta Analysis 75 Hepatitis C Genotype 75 Treated Patients 75 Patients Receiving 75 Naive Patients 75 Investigational Treatment 75 Disease Progression 75 Polymerase Inhibitor 75 Single Dose 75 Relapsed Multiple Myeloma 75 Patients Undergoing 75 Phase 2b Study 75 Advanced Solid Tumors 75 Metastatic Renal Cell Carcinoma 75 Treatment Naïve Patients 75 Pharmacokinetics PK 74 Chronic Myeloid Leukemia 74 Diabetic Patients 74 Vaccine Adjuvant 74 Improved Survival 74 Phospholipase A2 74 Completes Patient Enrollment 74 Subgroup Analysis 74 Improve Survival 74 Preclinical Data 74 Refractory Hodgkin Lymphoma 74 Demonstrated Significant 74 Potent Antiviral Activity 74 Colorectal Cancer Patients 74 Telaprevir VX 74 Hypertensive Patients 74 Radical Prostatectomy 74 JAK Inhibitor 74 Hormone Receptor Positive 74 Unfractionated Heparin 74 Study Showed 74 II Clinical Trial 74 Cardiovascular Events 74 Myelodysplastic Syndromes 74 Cutaneous T 74 Viral Load 74 Shows Promising 74 Presents Preclinical Data 74 Knee Osteoarthritis 74 alfa 2a 74 Investigational Drug 74 Clinical Trial Evaluating 74 Tolerability 74 Kinase Inhibitor 74 Relapsing Remitting Multiple Sclerosis 74 Hepatitis C Patients 74 Insulin Glargine 74 Phase III Trial 74 Pivotal Phase 74 Benign Prostatic Hyperplasia 74 First Patient Dosed 73 Clostridium difficile Infection 73 Immune Responses 73 Presents Positive 73 Adjunctive Therapy 73 Mouse Model 73 Initiate Phase 73 Phase III Clinical Trial 73 Orally Active 73 Chronic Constipation 73 Metastatic Melanoma 73 Proven Effective 73 Phase IIa Clinical Trial 73 Versus Placebo 73 Initiates Clinical Trial 73 Appears Safe 73 Resistant Hypertension 73 Shows Efficacy 73 Pediatric Patients 73 Significantly Reduces 73 Heart Failure Patients 73 Relapsed 73 Pulmonary Arterial Hypertension 73 Initiates Phase 73 Prophylactic Treatment 73 Significantly Improved 73 Controlled Study 73 Drug Resistant 73 Glufosfamide 73 Increased Risk 73 Patient Enrollment 73 Randomized Double Blind Placebo 73 Follicular Lymphoma 73 JAK2 Inhibitor 73 Plaque Psoriasis 73 Chemoradiation 73 Initiates Phase III 73 Vitro Activity 73 Hepatocellular Carcinoma 73 Phase 2a Trial 73 Randomized Phase II 73 Dendritic Cells 73 Granted Orphan Drug 73 Rotavirus Vaccine 73 Treatment Naive HIV 73 Statistically Significant 73 Hepatitis C Virus 73 Phase IIb Clinical Trial 73 Oral Cladribine 73 Treatment Naive 73 ST Elevation Myocardial 73 Clinical Efficacy 73 Virus Infection 72 Diffuse Large B 72 Preclinical Study 72 Fungal Infections 72 Dose Finding 72 Anticancer Activity 72 Present Preclinical Data 72 RNAi Therapeutic 72 Double Blind Placebo 72 Antitumor 72 Randomized Clinical Trial 72 Autologous Stem Cell Transplantation 72 Seasonal Allergic Rhinitis 72 Venous Thromboembolism 72 Malignant Melanoma 72 dasatinib Sprycel ® 72 Overactive Bladder 72 Diabetic Nephropathy 72 Treatment Reduces 72 sunitinib Sutent ® 72 Inflammatory Arthritis 72 Secondary Hyperparathyroidism 72 Localized Prostate Cancer 72 Drug Shows Promise 72 Treating Chronic 72 Critically Ill Patients 72 Pivotal Study 72 Unstable Angina Non 72 Investigational Agent 72 HER2 Positive Breast Cancer 72 Nucleoside 72 Pegylated Liposomal Doxorubicin 72 HCV Genotype 72 Non Responders 72 Node Positive 72 Recombinant Human 72 Significantly Reduced 72 Vicriviroc 72 Hepatitis B Virus 72 Peginterferon Alfa 2b 72 Renal Impairment 72 Antiviral Therapy 72 Sirolimus Eluting Stent 72 Placebo Controlled Trial 72 Initiates Phase II 72 Bone Metastases 72 PRN FDA Approves 72 Drug Combo 72 Gastric Cancer 72 Tumor Growth 72 Initiate Phase III 72 Newly Diagnosed 72 J Allergy Clin 72 Mg Usa 72 Pegylated Interferon 72 Inhaled Corticosteroids 72 Chronic Sinusitis 72 TO AVOID PREGNANCY WHILE 72 Clinical Outcome 72 Capecitabine 72 Hsp# Inhibitor 72 Randomized Double blind 72 Combination REOLYSIN R 72 Mylan Receives Approval 72 Statin Therapy 72 Cholesterol Lowering Drug 72 Tyrosine Kinase Inhibitor 72 Postmenopausal Osteoporosis 72 Epratuzumab 72 Protease Inhibitors 72 Atypical Hemolytic Uremic Syndrome 71 Peginterferon alfa 2a 71 Myelodysplastic Syndrome MDS 71 Chronic HCV 71 J Am Coll 71 Attenuates 71 Acute Ischemic Stroke 71 Randomized Study 71 Phase 2a Clinical Trial 71 PEGylated Fab fragment 71 Amgen Neulasta R 71 Neuroendocrine Tumors 71 Human Monoclonal Antibody 71 Breast Cancer Recurrence 71 Successfully Treated 71 Bare Metal Stents 71 Stent Implantation 71 Nitazoxanide 71 Partial Onset Seizures 71 achieved CCyR 71 Tezampanel 71 Invasive Fungal Infections 71 Solid Tumors 71 Vaccine Candidate 71 Topline Results 71 Files IND 71 Obese Patients 71 Bosutinib 71 Diabetic Foot Ulcer 71 Successfully Completes Phase 71 FDA Approvals 71 ritonavir boosted 71 Osteoporosis Drug 71 Serious Infections 71 Hematological Malignancies 71 Neoadjuvant Chemotherapy 71 Treat Anemia 71 Multiple Myeloma Patients 71 Colorectal Adenomas 71 Immunomedics Announces 71 Mg Uk 71 Osteoporosis Treatment 71 Ischemic Stroke 71 Cell Lymphoma 71 Teva Provides Update 71 Primary Hypercholesterolemia 71 Achieves Primary Endpoint 71 Renal Function 71 Albuferon TM 71 Pivotal Phase III 71 Novel Antibiotic 71 Fewer Side Effects 71 Initiates Clinical 71 Begins Dosing 71 Anticancer Drugs 71 Prospective Randomized 71 Experimental Vaccine 71 Chronic Lymphocytic Leukemia 71 COPEGUS R 71 Fast Track Status 71 Carboplatin Paclitaxel 71 Stent Restenosis 71 Aflibercept 71 Nat Clin Pract 71 Brain Metastases 71 Androgen Deprivation Therapy 71 Insulin Resistance 71 Parathyroid Hormone 71 Lupus Drug 71 Novel Mechanism 71 Gene Mutation 71 Carcinomas 71 Systemic Sclerosis 71 Acute Migraine 71 Myelofibrosis 71 Demonstrates Sustained 71 Low Dose 71 Shows Promise Against 71 FDA Clears 71 Interferon Beta 71 Kidney Transplant Patients 71 Preclinical Models 71 Medoxomil 71 CYP#A# CYP#D# 71 Oral Mucositis 70 Investigational Oral 70 Novel Inhibitor 70 FDA Okays 70 Chronic Heart Failure 70 Initiate Clinical Trial 70 Relapsed Refractory Multiple Myeloma 70 Hospital Acquired Pneumonia 70 Kidney Function 70 Predict Response 70 Novel Compound 70 Inhibits 70 Lung Cancer Patients 70 Prostate Cancer Patients 70 Tipranavir 70 Premenopausal Women 70 Pafuramidine 70 Adefovir 70 Randomized Clinical Trials 70 Placebo Controlled Study 70 Proves Effective 70 Anthracycline 70 Ovarian Cancer Patients 70 Slow Progression 70 Allergic Rhinitis 70 Lowers Risk 70 Acute Coronary Syndromes 70 FOLFOX6 70 Diabetic Neuropathy 70 Progressive Multifocal Leukoencephalopathy 70 Bladder Cancer 70 See CLINICAL PHARMACOLOGY 70 Demonstrates Efficacy 70 Late Breaker 70 First Patient Enrolled 70 Phase Ib Clinical Trial 70 Blood Pressure Lowering 70 SPRYCEL ® 70 Gene Variant 70 CCX# B 70 Immunogenicity 70 Commences Phase 70 Submits NDA 70 Epidermal Growth Factor Receptor 70 STELARA TM 70 Initiates Enrollment 70 Chronic Renal Failure 70 Randomized Controlled Trial 70 Fracture Risk 70 Renal Cancer 70 Disease Modifying 70 Carotid Stenting 70 Double Blind Randomized 70 Aggressive Prostate Cancer 70 Leukemias 70 Humanized Anti 70 Study Demonstrates 70 Liver Failure 70 Safety Tolerability 70 Prognostic Significance 70 Phase III Trials 70 Neoadjuvant 70 Releasing Factor 70 FDA APPROVES 70 Severe Asthma 70 Patients Enrolled 70 HER2 Positive 70 Cancer Incidence Mortality 70 Endometrial Cancer 70 Hematological Cancers 70 Randomized Phase III 70 Fludarabine 70 NICE Recommends 70 Receives Orphan Drug 70 Increased Mortality 70 Orthop Surg 70 Sirolimus Eluting 70 Active Rheumatoid Arthritis 70 Epilepsy Drug 70 Combo Therapy 70 Psoriasis Patients 70 Genes Predict 70 Gastric Ulcers 70 Treatment Regimen 70 Tiotropium 70 receiving INTRON 70 Zoledronic Acid 70 Treatment Resistant 70 Shows Promise 70 Randomized Trials 70 Radiofrequency Ablation 70 FDA Accepts 70 Monoclonal Antibody 70 First Patient Treated 70 Dose Ranging Study 70 J Am Acad 69 Glycemic Control 69 Respiratory Virus 69 investigational oral inhibitor 69 Kidney Transplant Recipients 69 Pneumococcal Vaccine 69 Perifosine KRX 69 IND Filing 69 Epoetin Alfa 69 Brentuximab Vedotin SGN 69 BARACLUDE ® 69 Xeloda ® 69 Vaccine Protects Against 69 NDA Submission 69 Efficacious 69 Antiretroviral Therapy 69 Anticancer Drug 69 MEK Inhibitor 69 Vaginal Gel 69 Gout Drug 69 Telbivudine 69 Metastatic Pancreatic Cancer 69 Boceprevir 69 Artery Disease 69 Initiates Dosing 69 Effectively Treats 69 HBeAg + 69 Cyclophosphamide 69 Viral Suppression 69 Oral Calcitonin 69 Receives Fast Track 69 Breast Cancer Patients 69 Copegus ribavirin 69 J Clin 69 Acute Myocardial Infarction 69 Dose Ranging 69 interferon beta 1a infertility 69 Increases Risk 69 Invasive Breast Cancer 69 brand ciclesonide HFA 69 Data Suggest 69 Drug Prevents 69 ORLive Presents 69 Oral Interferon 69 Placebo Controlled 69 LENALIDOMIDE 69 PEGINTRON TM 69 Nephrol 69 Lupus Nephritis 69 metastatic malignant 69 Potentially Fatal 69 Sangamo BioSciences Announces 69 Diabetic Neuropathic Pain 69 myelodysplastic myeloproliferative diseases 69 Fixed Dose 69 neutropenia dehydration dyspnea 69 Transdermal Patch 69 Endothelial Cells 69 Generic Version 69 Acute Heart Failure 69 Left Ventricular Dysfunction 69 Beneficial Effects 69 Therapeutic Vaccine 69 Bevacizumab 69 familial amyloidotic polyneuropathy FAP 69 Sustained Virologic Response 69 Study Evaluates 69 Anti CD# Antibody 69 Study Shows Promise 69 ribavirin RBV 69 Crit Rev 69 FDA Approves Drug 69 Slows Progression 69 Hypercholesterolemia 69 Treatment Shows Promise 69 Demonstrate Significant 69 Posaconazole 69 Neurol 69 Nilotinib 69 Eluting Stent 69 Initiates Clinical Trials 69 Multicenter Trial 69 Endovascular Treatment 69 J Shoulder Elbow 69 virus HCV protease inhibitor 69 Inflammatory Markers 69 Myeloid 69 imatinib Gleevec ® 69 developing Bicifadine serotonin 69 BCG refractory carcinoma 69 Receives Approvable Letter 69 Reduces Mortality 69 essential thrombocythemia ET 69 DIRECT Trial 69 Clinically Significant 69 Receptor Antagonist 69 Breast Cancer Treatment 69 Paroxysmal Nocturnal Hemoglobinuria PNH 69 Erectile Dysfunction Drug 69 Rheumatoid Arthritis Drug 69 Aurora Kinase 69 Cardiovascular Outcomes 69 Enlarged Prostate 69 Spectrum Pharmaceuticals Announces 69 Predict Risk 69 Proc Am Soc 69 Glatiramer Acetate 69 J Pediatr 69 HBeAg negative 69 Complete Remission 69 Ranolazine 69 Chronic Bronchitis 69 Lenalidomide 69 Relapsed Refractory Aggressive 69 Melphalan 69 Breast Cancers 69 Irinotecan 69 Paraplatin ® 69 Lymphocytic 69 Pharmacyclics Announces 69 By JENNIFER LEARN 69 IIa Clinical Trial 68 PEG IFN 68 Minimally Invasive Treatment 68 Copegus ® 68 Virologic 68 Chemotherapy Regimen 68 Chemotherapy Improves 68 dependent kinase inhibitor 68 Septic Shock 68 Safinamide 68 Recurrent Breast Cancer 68 Int J Radiat Oncol 68 Oral Laquinimod 68 Cognitive Impairment 68 IN PATIENTS WITH 68 metastatic castration resistant 68 Dual Antiplatelet Therapy 68 R lenalidomide 68 Novel Therapeutic 68 Prostate Cancer Vaccine 68 Allogeneic 68 Stent Thrombosis 68 Systemic Delivery 68 Presents Preclinical 68 Nebulized 68 Hepatitis C Treatment 68 5 FU leucovorin 68 Poorly Controlled 68 Stable Coronary Artery 68 trastuzumab Herceptin R 68 Efficacy Results 68 Neovascular Age Related Macular 68 Telithromycin 68 Reduces Risk 68 Acute Attacks 68 Non Alcoholic Fatty 68 Pivotal Trial 68 Gene Variation 68 Sipuleucel T 68 Rectal Cancer 68 Bortezomib 68 Idiopathic Pulmonary Fibrosis 68 Osteoporosis Drugs 68 Lamivudine 68 Receptor Agonist 68 Valopicitabine 68 Prognostic Value 68 Lung Cancer Drug 68 Cardiac Resynchronization 68 Receives Milestone Payment 68 Demonstrates Potential 68 Premature Infants 68 Novel Treatments 68 toenail onychomycosis 68 peginterferon alfa 2a Pegasys 68 Genital Herpes 68 Newly Diagnosed Patients 68 oral nucleoside analogue 68 Antigen Specific 68 Physical Function 68 Nicotine Vaccine 68 humanized interleukin 6 68 carcinoma mCRC 68 AVASTIN 68 Recurrent Ovarian Cancer 68 CYT# potent vascular disrupting 68 Therapeutic Vaccines 68 Desvenlafaxine Succinate 68 Cardiol 68 ORENCIA ® 68 Multicenter Study 68 treatment naive genotype 68 Stem Cell Transplants 68 Showed Significant 68 Interferon alfa 2b 68 Therapy Improves 68 evaluating picoplatin 68 Mycophenolate Mofetil 68 oral prodrug 68 Chemotherapy Induced 68 Adenoviral 68 Prognostic Factors 68 Injection Site 68 Efficacy Trial 68 bone marrow reticulin deposition 68 Long Term Outcomes 68 lenalidomide Revlimid R 68 FEMALES SHOULD BE ADVISED 68 Positive Opinion 68 PEGylated anti 68 nucleoside naive 68 Announces Initiation 68 Gastrointestinal Stromal Tumors 68 evaluating tivozanib 68 ACE Inhibitors 68 Total Knee Arthroplasty 68 Pegylated 68 Sustained Efficacy 68 Oral Formulation 68 Prostate Tumors 68 Chronic Lymphocytic Leukemia CLL 68 Liver Metastases 68 Bipolar Mania 68 adalimumab Humira 68 Vildagliptin 68 ST Segment Elevation 68 Eur J 68 Arthritis Drug 68 Receives Positive Opinion 68 Am J Obstet 68 Topical Treatment 68 Anticancer Agent 68 Targeted Therapy 68 HBeAg positive 68 Systematic Review 68 Lung Cancer Trial 68 Schizophrenia Drug 68 Hepatitis B Vaccine 68 ceftazidime 68 Oral Anticoagulant 68 Cardiac Function 68 Menopausal Women 68 Migraine Pain 68 R Saizen R 68 Mouse Models 68 Breast Tumors 68 Panic Disorder 68 Antiviral Drugs 68 Curr Opin 68 Boosts Survival 68 Phase IIa Trial 68 Arch Facial Plast 68 Darunavir 68 recurrent glioblastoma multiforme 67 Zorbtive TM 67 alfa 2b 67 Sandostatin R 67 Left Ventricular 67 Anti TNF 67 Hepatitis C Infection 67 Seasonal Influenza Vaccine 67 Cethromycin 67 Dose Escalation Study 67 Emerging Therapies 67 erlotinib Tarceva ® 67 Enoxaparin 67 Philadelphia Chromosome Positive 67 bevacizumab Avastin R 67 Respiratory Syncytial Virus 67 Asymptomatic 67 Xenografts 67 Nephrol Dial Transplant 67 Coronary Stents 67 Phase 1b Clinical Trial 67 hypertrichosis occurred 67 Catheter Ablation 67 Drug Fails 67 severe oral mucositis 67 Circulating Tumor Cells 67 Atypical Antipsychotics 67 Gene Linked 67 stage IIIB 67 Prostate Biopsy 67 Randomised Trial 67 Juvenile Idiopathic Arthritis 67 Fondaparinux 67 oropharyngeal candidiasis OPC 67 ALN HPN 67 Gene Variants 67 Platinol ® 67 Refractory Multiple Myeloma 67 Therapeutic Efficacy 67 Diabetic Kidney Disease 67 Initiates Phase 2b 67 non splenectomized 67 Acute Pancreatitis 67 Long Term Survival 67 Erlotinib 67 Liver Tumors 67 Phase III Pivotal 67 severe neutropenia 67 HDAC Inhibitor 67 Depressive Symptoms 67 5 Fluorouracil 67 Multicenter Randomized Double 67 Skeletal Muscle 67 BARACLUDE R 67 pyrexia mucositis sepsis febrile 67 J Am Soc 67 Improve Outcomes 67 Randomized Controlled Trials 67 J Consult Clin 67 Ovitrelle R Serostim 67 Confirmatory Phase 67 Hormone Therapy 67 Thromboembolism 67 Patient Treated 67 Multicenter Randomized 67 Nuvelo Announces 67 TNF Tumor Necrosis Factor 67 Vaccine Prevents 67 Ann Oncol 67 Ischemic 67 cetuximab Erbitux R 67 Ozarelix 67 Expanded Indication 67 patients coinfected 67 relapsed MM 67 non nucleoside inhibitor 67 Pharmacodynamics 67 Unstable Angina 67 metastatic colorectal carcinoma 67 Synthetic Peptide 67 Interferon Gamma 67 Genetic Variation 67 Taxane 67 Significantly Improves 67 Psychiatric Disorders 67 Left Ventricular Hypertrophy 67 Pancreatic Adenocarcinoma 67 abacavir lamivudine 67 alpha 2a 67 Squamous 67 Adenoma 67 Hedgehog Pathway 67 Heterozygous Familial Hypercholesterolemia 67 Peginterferon alfa 2b 67 Community Acquired Pneumonia 67 Pregnancy Linked 67 Cholesterol Drug 67 Commence Phase 67 Angiogenic 67 Breast Cancer Cells 67 stage IIIb IV 67 Child Adolesc Psychiatry 67 Hyperlipidemia 67 Ecallantide 67 PEGASYS ® 67 FUSILEV enhances 67 Paclitaxel Carboplatin 67 Bivalirudin 67 Romiplostim 67 Drug Resistant TB 67 Lipid Levels 67 Androgen Receptor 67 Arch Neurol 67 Induces 67 Am J Clin 67 atazanavir sulfate 67 q8h 67 Newly Diagnosed Breast Cancer 67 Collaborators Present 67 Blood Clots 67 Endocrinol 67 Reduced Risk 67 Dialysis Patients 67 Intravenous Formulation 67 J Acquir Immune Defic 67 Thrombotic 67 TNF Blockers 67 novel VDA molecule 67 Vitrasert R 67 Adjunctive 67 Clinical Trial Data 67 Receives Marketing Authorization 67 topical gel formulation 67 Genotypes 67 AASLD Meeting 67 Natalizumab 67 Platelet Inhibition 67 Cancer Patients Treated 67 Aliskiren 67 Atypical Antipsychotic 67 Tocilizumab 67 Rheumatoid Arthritis RA 67 Abiraterone Acetate 67 myocardial infarction ventricular fibrillation 67 Cholesterol Drugs 67 Diabetic Macular Edema 67 Abciximab 67 Syncria R 67 Migraine Drug 67 Inflammatory Disease 67 Subtype 67 Dasatinib 67 Test Detects 67 Chronic Pelvic Pain 67 R bisoprolol Euthyrox 67 Inherited Diseases 67 Urinary Incontinence 67 Contrast Agents 67 Syndr 67 Subtypes 67 Lanthanum Carbonate 67 See WARNINGS 67 8mg/kg 67 Successfully Treats 67 infliximab monotherapy 67 Stem Cell Treatment 67 Patent Covering 67 Bisphosphonate 67 Non Alcoholic Steatohepatitis 67 ® lenalidomide 67 Milestone Payment 67 ribavirin USP 67 Nymox NX 67 Tigecycline 67 #-# Full Text 67 Decitabine 67 following fluoropyrimidine oxaliplatin 67 Enrolls First 67 Interferon beta 1a 67 Skin Structure Infections 67 administered concomitantly 67 TB Vaccine 67 Personalized Immunotherapy 67 vapreotide acetate 67 Anti Inflammatory Drug 67 Antipsychotic 67 LymphoStat B belimumab 67 ergot derivatives 67 R roscovitine CDK cyclin 67 ribavirin Copegus 67 RNAi Therapeutics 66 indinavir Crixivan 66 Bone Fractures 66 FOLFOX6 chemotherapy regimen 66 Obesity Linked 66 Prospective Randomized Trial 66 cisplatin gemcitabine 66 Smallpox Vaccine 66 Anticoagulant 66 Acetate Rectal Suppositories 66 Advanced Gastric Cancer 66 Announcement acc 66 Selective Inhibitor 66 Chemotherapeutic Agents 66 Prove Effective 66 receiving VELCADE 66 Obstet Gynecol 66 Gemzar ® 66 Clin Oncol 66 Anemia Drug 66 Randomized Controlled 66 Pegasys ® 66 Ann Rheum Dis 66 Myelodysplastic Syndrome 66 Antifungal 66 treatment naïve genotype 66 Confirms Efficacy 66 Inhaled Nitric Oxide 66 pan histone deacetylase 66 abacavir Ziagen 66 Treating Heart Failure 66 diarrhea predominant irritable 66 dual endothelin receptor antagonist 66 CYP#A# substrate 66 Smoking Linked 66 TRANSFORMS 66 Pegloticase 66 Post Operative 66 Metabolic Efficiency 66 erlotinib Tarceva R 66 J Foot Ankle 66 refractory chronic lymphocytic 66 ACTEMRA TM 66 Antiplatelet Therapy 66 Stomach Cancer 66 Anti Clotting Drug 66 unfractionated heparin UFH 66 chronic hepatitis B. 66 Blind Placebo Controlled Trial 66 Sustained Reduction 66 Nat Rev 66 PEGylated interferon beta 1a 66 Cell Transplants 66 Respiratory Distress 66 Kidney Transplants 66 Controlled Clinical Trial 66 Polyneuropathy 66 Lung Cancers 66 Combination Vaccine 66 Diabetic Foot Ulcers 66 R# #mg BID 66 Randomized Comparison 66 Refractory Peripheral T 66 Neulasta R 66 Bone Mineral Density 66 Biogen Genentech 66 Multicenter Phase 66 Prophylaxis 66 known dihydropyrimidine dehydrogenase 66 Darbepoetin Alfa 66 Free Full Text 66 Maribavir 66 ISTODAX ® 66 Malignant Glioma 66 Camptosar ® 66 colesevelam HCl 66 Immunosuppression 66 Multiple Myeloma MM 66 Sleep Disturbances 66 FASLODEX 66 See CONTRAINDICATIONS 66 Non Invasive Treatment 66 Laryngeal Cancer 66 Ovarian Cancers 66 chronic eosinophilic leukemia 66 Percutaneous Tibial Nerve Stimulation 66 Pemetrexed 66 Drug Regimen 66 ribavirin Copegus ® 66 Intracerebral Hemorrhage 66 Linezolid 66 Dermatol 66 Severe Acne 66 Vasomotor Symptoms 66 Immunotherapeutic 66 Oncolytic 66 polymerase inhibitor 66 pegylated interferon alfa 2a 66 Less Invasive 66 Bipolar Depression 66 BENLYSTA TM 66 Inflammatory Diseases 66 Omacetaxine 66 Factor Receptor 66 Interferon Alpha 66 Effective Than 66 Selective Cardiac Myosin 66 Pediatr 66 Pivotal Trials 66 Fludara ® 66 Antidepressants Linked 66 Fluorouracil 66 Adalimumab 66 Systemic Lupus Erythematosus 66 Ondansetron Injection USP 66 Patient Enrolment 66 Am J Respir 66 Autoimmune Diseases 66 Antibody Drug Conjugate 66 tenofovir emtricitabine 66 Therapeutic Potential 66 pralatrexate injection folate analogue